Semaglutide results in men: separating the evidence from the expectations

The biggest myth: men don't respond as well to semaglutide

The most common misconception a question our prescribers hear most weeks is that semaglutide simply works less well in men than in women. The reality is more nuanced. Both sexes lose significant weight in clinical trials, but the path looks different. In the STEP 1 trial, published in the New England Journal of Medicine, average weight loss across all participants on semaglutide 2.4 mg reached approximately 15% over 68 weeks. Sub-group analyses consistently show that men lose a similar or slightly smaller percentage of body weight compared to women, but because men typically start at a higher absolute weight, the kilogram reduction is often comparable or greater. Losing 13–14% of 130 kg is a different number on the scales to losing 16% of 95 kg.

The mechanism doesn't discriminate by sex. Semaglutide activates GLP-1 receptors in the brain and gut, slowing gastric emptying and dampening appetite signals. Those pathways work the same way in male physiology. What differs is body composition: men generally carry a higher proportion of muscle, which means total body fat percentage may shift more dramatically than the weight reading alone suggests. Men in the STEP trials reported reduced hunger, fewer food cravings and a noticeable drop in portion size within the first weeks. Early signs in the first week are often appetite-related rather than scale-related, and that pattern holds for men and women alike.

When men tend to see results, and what shapes the timeline

Weight loss on semaglutide is not linear, and men sometimes notice a different pattern to what they expect. The first month is largely a settling-in period. The starting dose is low by design, intended to help the body adjust rather than to drive weight loss immediately. Most men report little to no scale movement in weeks one to four, which can be discouraging if the expectation was rapid change. What to expect at four weeks is worth reading before that frustration sets in.

From months two to four, as the dose steps up, appetite suppression becomes more pronounced and weight loss typically accelerates. Men who combine treatment with higher protein intake and resistance training tend to preserve lean muscle while losing fat, which is clinically preferable and may explain why some men find their body composition improves even when the scales move slowly. Visceral fat, the type stored around the organs and linked to cardiovascular risk, is particularly responsive to the calorie deficit that semaglutide helps create. By six months, trial data shows most men on the maintenance dose have lost between 8% and 12% of their starting weight, with further loss continuing to the 68-week mark for those who stay on treatment. The full timeline of how long Wegovy takes to work puts those phases in context.

Individual variation is real. Genetics, sleep quality, alcohol consumption and the severity of any underlying metabolic conditions all influence outcomes. A man with well-controlled type 2 diabetes may see slower weight loss than one without it. None of this makes treatment less worthwhile; it makes realistic expectation-setting more important.

Preserving muscle and managing side effects: the male-specific practicalities

One practical consideration that comes up more often for men is muscle preservation. Semaglutide works partly by reducing overall calorie intake. If protein intake falls significantly alongside calories, some muscle loss can occur alongside fat loss. This is not unique to men, but it matters more when starting muscle mass is higher and the goal includes body composition, not just the number on the scales. Clinical guidance suggests aiming for adequate dietary protein and maintaining some form of resistance activity throughout treatment. Personal plans belong with a prescriber or dietitian, but the principle is well-established in the literature.

Side effects follow a similar profile regardless of sex. Nausea, looser stools and reduced appetite are the most commonly reported, particularly at the start of a new dose. They are generally mild and settle within days to a fortnight for most people. Men sometimes report that they underestimated how dramatically their appetite would change, finding it genuinely difficult to eat enough protein when hunger signals quieten substantially. That adjustment is manageable with some planning. The NHS overview of semaglutide lists the full side-effect profile clearly and is worth reading before starting.

Anyone experiencing severe, persistent abdominal pain that spreads to the back should seek urgent medical attention. The MHRA has highlighted acute pancreatitis as a known but infrequent risk with GLP-1 medicines. Report any unexpected side effects through the Yellow Card scheme.

Semaglutide or tirzepatide: a question worth raising at consultation

Men researching semaglutide results often come across the head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, which compared tirzepatide against semaglutide 2.4 mg over 72 weeks. Tirzepatide produced greater average weight loss in that trial. The newer data on Wegovy results specifically in men and the evidence on tirzepatide both inform a clinical conversation about which medicine suits a given individual. Neither is right for everyone, and suitability depends on the whole picture: medical history, other medicines, preferences and goals.

Semaglutide at the higher 7.2 mg maintenance dose, approved by the MHRA in 2026, has shown around 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide. Whether a particular dose or medicine is appropriate is something a prescriber assesses, not something to decide from a webpage. How long Wegovy treatment typically lasts is another practical question worth understanding before committing to a plan. For a fuller picture of the treatment itself, the Wegovy overview covers licensing, how it works and what to expect from the process. If cost is part of your thinking, Wegovy pricing in the UK explains what private treatment currently involves.

If you'd like a prescriber to look at your situation properly, speaking to our prescribers through a free consultation is the straightforward next step. There's no commitment, and your answers are reviewed by a real clinician the same day.